GlassScriptPhysician profile
Johnny Lee Gerardot
NPI 1336673037
$3,562.20
in general payments reported to CMS, 2019-2025
31 companies · $65.34 in 2025
The $65.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $326 · 2021: $1,311 · 2022: $1,208 · 2023: $255 · 2024: $398 · 2025: $65.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.52 | 2020-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.19 | 2020-2022 | |
| Abbvie INC. | $276.65 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $268.12 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.41 | 2021-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $181.01 | 2021 | |
| Glaxosmithkline, LLC. | $152.67 | 2020-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $144.66 | 2024 | Watchman Flx |
| Dexcom, INC. | $138.70 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $130.59 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $129.13 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $127.97 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $120.49 | 2020-2023 | M-M-R II, Vaxneuvance, Vaxelis |
| Biohaven Pharmaceutical Holding Company LTD. | $115.48 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.35 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $94.94 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.57 | 2022 | |
| Eisai INC. | $64.86 | 2021-2022 | |
| Amgen INC. | $59.25 | 2021-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $47.68 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $39.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.48 | 2022 | |
| Paratek Pharmaceuticals, INC. | $33.97 | 2021-2022 | |
| Terumo Medical Corporation | $32.95 | 2024-2025 | Hydropearl |
| Lilly USA, LLC | $26.14 | 2022 | |
| Tris Pharma INC | $18.16 | 2023 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $13.56 | 2020 | |
| Esperion Therapeutics, INC. | $12.91 | 2021 | |
| Genentech USA, INC. | $12.09 | 2021 | |
| Dermira, INC. | $11.47 | 2020 | |
| Insulet Corporation | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Gerardot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.